Exelixis Inc
NASDAQ:EXEL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.17
36.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Exelixis Inc
Wall Street
Price Targets
EXEL Price Targets Summary
Exelixis Inc
According to Wall Street analysts, the average 1-year price target for
EXEL
is 33.71 USD
with a low forecast of 23.23 USD and a high forecast of 42 USD.
EXEL Last Price Targets
Exelixis Inc
The latest public price target was made on Oct 30, 2024 by
Joseph Catanzaro
from
Piper Sandler
,
who expects
EXEL
stock to
rise by 8%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Joseph Catanzaro
Piper Sandler
|
36
USD
Upside 8% |
1 month ago
Oct 30, 2024
|
Exelixis price target raised to $36 from $33 at Piper Sandler
TheFly
|
David Lebowitz
Citigroup
|
38
USD
Upside 14% |
1 month ago
Oct 30, 2024
|
Exelixis (EXEL) PT Raised to $38 at Citi
StreetInsider
|
Etzer Darout
BMO Capital
|
36
USD
Upside 8% |
1 month ago
Oct 30, 2024
|
Exelixis (EXEL) PT Raised to $36 at BMO Capital
StreetInsider
|
Asthika Goonewardene
Truist Financial
|
38
USD
Upside 14% |
1 month ago
Oct 30, 2024
|
Exelixis price target raised to $38 from $33 at Truist
TheFly
|
Kennen MacKay
RBC Capital
|
34
USD
Upside 2% |
2 months ago
Oct 16, 2024
|
Exelixis (EXEL) PT Raised to $34 at RBC Capital
StreetInsider
|
|
Christopher Liu
Leerink Partners
|
28.5
USD
Downside 14% |
2 months ago
Oct 16, 2024
|
Leerink Partners Reiterates Market Perform Rating on Exelixis (EXEL)
StreetInsider
|
Chris Shibutani
Goldman Sachs
|
18
USD
Downside 46% |
2 months ago
Oct 16, 2024
|
Goldman Sachs Reiterates Sell Rating on Exelixis (EXEL)
StreetInsider
|
Akash Tewari
Jefferies
|
33
USD
Downside 1% |
2 months ago
Oct 15, 2024
|
Exelixis price target raised to $33 from $30 at Jefferies
TheFly
|
Jeffrey Hung
Morgan Stanley
|
30
USD
Downside 10% |
2 months ago
Oct 15, 2024
|
Morgan Stanley Out Mixed on Exelixis (EXEL), PT Raised to $30, 'ruling is short of a home run scenario'
StreetInsider
|
|
Asthika Goonewardene
Truist Financial
|
33
USD
Downside 1% |
2 months ago
Oct 14, 2024
|
Truist Securities Reiterates Buy Rating on Exelixis (EXEL)
StreetInsider
|
|
Sudan Loganathan
Stephens
|
23
USD
Downside 31% |
2 months ago
Oct 14, 2024
|
Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
StreetInsider
|
|
Jeffrey Hung
Morgan Stanley
|
28
USD
Downside 16% |
2 months ago
Oct 11, 2024
|
Exelixis price target raised to $28 from $26 at Morgan Stanley
TheFly
|
Ashwani Verma
UBS
|
30
USD
Downside 10% |
3 months ago
Sep 19, 2024
|
Exelixis initiated with a Neutral at UBS
TheFly
|
|
David Lebowitz
Citigroup
|
31
USD
Downside 7% |
3 months ago
Sep 16, 2024
|
Citi Reiterates Buy Rating on Exelixis (EXEL)
StreetInsider
|
Jason Gerberry
Bank of America Securities
|
30
USD
Downside 10% |
3 months ago
Sep 4, 2024
|
Exelixis (EXEL) PT Raised to $30 at BofA Securities
StreetInsider
|
|
Robert Burns
H.C. Wainwright
|
29
USD
Downside 13% |
4 months ago
Aug 8, 2024
|
Exelixis (EXEL) PT Raised to $29 at H.C. Wainwright
StreetInsider
|
Silvan Tuerkcan
JMP Securities
|
29
USD
Downside 13% |
4 months ago
Aug 7, 2024
|
Exelixis price target raised to $29 from $27 at JMP Securities
TheFly
|
|
David Lebowitz
New Street
|
31
USD
Downside 7% |
7 months ago
May 20, 2024
|
Citi Reiterates Buy Rating on Exelixis (EXEL)
StreetInsider
|
|
George Farmertzer Darout
BMO Capital
|
29
USD
Downside 13% |
7 months ago
May 20, 2024
|
BMO Capital Reiterates Outperform Rating on Exelixis (EXEL)
StreetInsider
|
Peter Lawson
Barclays
|
25
USD
Downside 25% |
8 months ago
Apr 11, 2024
|
Barclays Downgrades Exelixis (EXEL) to Equalweight
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is EXEL's stock price target?
Price Target
33.71
USD
According to Wall Street analysts, the average 1-year price target for
EXEL
is 33.71 USD
with a low forecast of 23.23 USD and a high forecast of 42 USD.
What is Exelixis Inc's Revenue forecast?
Projected CAGR
11%
For the last 8 years the
compound annual growth rate for
Exelixis Inc's revenue is
63%.
The projected
CAGR
for the next 4 years is
11%.
What is Exelixis Inc's Operating Income forecast?
Projected CAGR
52%
The
compound annual growth rate
of Exelixis Inc's operating income for the next 4 years is
52%.
What is Exelixis Inc's Net Income forecast?
Projected CAGR
44%
The
compound annual growth rate
of Exelixis Inc's net income for the next 4 years is
44%.
You don't have any saved screeners yet
